Article Text

other Versions

PDF
Activated innate immune system in irritable bowel syndrome?
  1. Jost Langhorst (jost.langhorst{at}gmx.de)
  1. Department of Internal and Integrative Medicine, University of Duisburg-Essen, Kliniken Essen-Mitte, Germany
    1. Angela Wieder (angwie{at}gmx.de)
    1. Department of Internal and Integrative Medicine, University of Duisburg-Essen, Kliniken Essen-Mitte, Germany
      1. Andreas Rueffer (anrue{at}gmx.de)
      1. Labor L+S AG, Bad Bocklet-Groβenbrach, Germany
        1. Andreas Michalsen (anmi{at}gmx.de)
        1. Department of Internal and Integrative Medicine, University of Duisburg-Essen, Kliniken Essen-Mitte, Germany
          1. Frauke Musial (mufrau{at}gmx.de)
          1. Department of Internal and Integrative Medicine, University of Duisburg-Essen, Kliniken Essen-Mitte, Germany
            1. Gustav J Dobos (gujdob{at}gmx.de)
            1. Department of Internal and Integrative Medicine, University of Duisburg-Essen, Kliniken Essen-Mitte, Germany

              Abstract

              The discovery of antimicrobial peptides has extended the knowledge of unspecific defense mechanisms. In addition to the physical barrier, the intestinal epithelium contributes to host defense by producing antimicrobial peptides to limit access to enteric bacteria and other microorganisms1. The production of inducible antimicrobial peptides offers a first and rapid defence response of epithelial cells against invading microbes2. Human β-defensin-2 (HBD-2) was the first inducible human anti-microbial protein discovered3. It can be induced by probiotic microorganisms and pro-inflammatory cytokines4. Recent results suggest, that HBD-2 is expressed in active intestinal inflammation, especially in ulcerative colitis5. Thus far, the expression of beta- defensins has been quantified in the intestinal mucosa by using polymerase-chain reaction. Our aim was to evaluate fecal measurements of HBD-2 in patients with active ulcerative colitis (UC), compared to irritable bowel syndrome (IBS) as a non-inflammatory clinical control and healthy controls (HC). We expected that faecal HBD-2 levels would show a similar pattern compared to mucosal HBD-2 and thus should be elevated in UC selectively.

              • HBD-2 in feces
              • innate immunity
              • defensins
              • irritable bowel syndrome
              • ulcerative colitis

              Statistics from Altmetric.com

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.